Two different treatment regimens of ranibizumab 0.5 mg for neovascular age‐related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study

PURPOSE: To evaluate the efficacy and safety of monthly and pro re nata (PRN, guided by visual acuity stabilization and disease activity criteria) ranibizumab regimens in Chinese patients with neovascular age‐related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoxin, Zhu, Qi, Egger, Anna, Chang, Liu, Wolf, Sebastian, Song, Yanping, Zhang, Junjun, Dong, Fangtian, Xu, Xun, Weisberger, Annemarie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247421/
https://www.ncbi.nlm.nih.gov/pubmed/33377611
http://dx.doi.org/10.1111/aos.14588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247421/
https://www.ncbi.nlm.nih.gov/pubmed/33377611
http://dx.doi.org/10.1111/aos.14588

Ejemplares similares